EXHIBIT 10.6

                               AMENDMENT SEVEN TO
                              DEVELOPMENT AGREEMENT

         This Amendment Seven, with an effective date of October 6, 2000,
between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and An Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001, Amendment Three dated May 12, 2001,
Amendment Four dated May 13, 2001, Amendment Five dated May 13, 2001 and
Amendment 6 dated 12/05/01 (hereinafter individually and collectively
"Development Agreement") and which the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Seven clarify that
Paragraph 5.1 of the Confidentiality clause includes all interactions between
the parties during the term of this Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.       For consistency and unless otherwise defined herein all initially
         capitalized terms shall have the meaning set forth in the Development
         Agreement.

2.       Paragraph 5. 1, replace line 11 through the end of the sentence on line
         12 to read: ".... in connection with the interaction between the
         parties during the term of this Agreement.." Lines 12-13: delete "To
         the extent that disclosure is authorized by this Agreement," and begin
         that sentence with "Prior to the disclosure..."

         Incorporation of the changes identified above results in Paragraph 5.1
to now read as follows:

         5.1      Confidential Information. During the term of this Agreement,
                  and five (5) years thereafter, following the expiration or
                  earlier termination hereof, each party shall exercise
                  reasonable care to maintain in confidence all information of
                  the other party (including samples) disclosed by the other
                  party and identified at the time of disclosure, to be
                  confidential ("Confidential Information"), and shall not use,
                  disclose or grant the use of the Confidential Information
                  except on a need-to-know basis to those directors, officers,
                  employees, agents, permitted sublicensces and permitted
                  assignees, to the extent such disclosure is reasonably
                  necessary in connection with the interaction between the
                  parties during the term of this



                  Agreement. Prior to disclosure, each party hereto shall obtain
                  the written agreement of any such Person, who is not otherwise
                  bound by fiduciary obligations to such party, to hold in
                  confidence and not make use of the Confidential Information
                  for any purpose other than those permitted by this Agreement.
                  Each party shall notify the other promptly upon discovery of
                  the any unauthorized use or disclosure of the other party's
                  Confidential Information.

         3.       Unless expressly amended by this Amendment Seven, all other
                  terms and conditions of the Development Agreement shall remain
                  in full force and effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

         SRI:                          LSI:
         SRI International             Lipid Sciences, Incorporated

         By: /s/ V. Rene Harmount      By:  /s/ Phil Radlick
             ------------------------      -----------------
             V. Rene Harmount              Phil Radlick, Ph.D.
             Group Manager, Contracts      President and Chief Executive Officer

                                       2